MX352906B - Fragmentos de la subunidad pa de rna polimerasa dependiente de rna del virus pandemico h1n1 2009 de influenza a y su uso. - Google Patents

Fragmentos de la subunidad pa de rna polimerasa dependiente de rna del virus pandemico h1n1 2009 de influenza a y su uso.

Info

Publication number
MX352906B
MX352906B MX2012010652A MX2012010652A MX352906B MX 352906 B MX352906 B MX 352906B MX 2012010652 A MX2012010652 A MX 2012010652A MX 2012010652 A MX2012010652 A MX 2012010652A MX 352906 B MX352906 B MX 352906B
Authority
MX
Mexico
Prior art keywords
subunit
compounds
polypeptide
relates
polypeptide fragments
Prior art date
Application number
MX2012010652A
Other languages
English (en)
Other versions
MX2012010652A (es
Inventor
Cusack Stephen
Kowalinski Eva
Zubieta Chloe
Original Assignee
European Molecular Biology Laboratory Embl Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by European Molecular Biology Laboratory Embl Star filed Critical European Molecular Biology Laboratory Embl Star
Publication of MX2012010652A publication Critical patent/MX2012010652A/es
Publication of MX352906B publication Critical patent/MX352906B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/30—Drug targeting using structural data; Docking or binding prediction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Theoretical Computer Science (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)

Abstract

La presente invención se refiere a fragmentos de polipéptido que comprenden un fragmento amino-terminal de la subunidad PA de una RNA polimerasa dependiente de RNA viral que posee actividad de endonucleasa, en donde la subunidad PA es de virus pandémico H1N1 2009 de Influenza A o es una variante del mismo. Esta invención también se refiere a (i) cristales de los fragmentos de polipéptido que son adecuados para la determinación estructural de los fragmentos de polipéptido que usan cristalografía de rayos X y(ii) métodos computacionales que usan las coordenadas estructurales del polipéptido para clasificar y diseñar compuestos que modulan, de manera preferente inhiben el sitio endonucleolíticamente activo dentro del fragmento de polipéptido. Además, esta invención se refiere a métodos para identificar compuestos que se enlazan a los fragmentos de polipéptido PA que poseen actividad de endonucleasa e inhiben de manera preferente la actividad endonucleolítica, de manera preferente en un entorno de alto rendimiento. Esta invención también se refiere a compuestos que son capaces de modular, de manera preferente de inhibir, la actividad de endonucleasa del fragmento de polipéptido de subunidad PA o variante del mismo de la presente invención y composiciones farmacéuticas que comprenden los compuestos para el tratamiento de condiciones de enfermedad provocadas por infecciones virales con virus de la familia Orthomyxoviridae, de la de la familia Bunyaviridae y/o de la de la familia Arenviridae, provocadas de manera preferente por infecciones virales con virus pandémico H1N1 2009 de Influenza A. De manera preferente, los compuestos son identificables por los métodos dados a conocer en este documento o las composiciones farmacéuticas son producibles por los métodos dados a conocer en este documento.
MX2012010652A 2010-03-16 2011-03-15 Fragmentos de la subunidad pa de rna polimerasa dependiente de rna del virus pandemico h1n1 2009 de influenza a y su uso. MX352906B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34033510P 2010-03-16 2010-03-16
PCT/EP2011/001274 WO2011113579A2 (en) 2010-03-16 2011-03-15 Influenza a 2009 pandemic h1n1 polypeptide fragments comprising endonuclease activity and their use

Publications (2)

Publication Number Publication Date
MX2012010652A MX2012010652A (es) 2013-02-07
MX352906B true MX352906B (es) 2017-12-13

Family

ID=43983275

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012010652A MX352906B (es) 2010-03-16 2011-03-15 Fragmentos de la subunidad pa de rna polimerasa dependiente de rna del virus pandemico h1n1 2009 de influenza a y su uso.

Country Status (12)

Country Link
US (3) US9181307B2 (es)
EP (1) EP2547696B1 (es)
JP (2) JP2013521786A (es)
KR (1) KR20130075726A (es)
CN (2) CN105273066A (es)
AU (1) AU2011229469B2 (es)
BR (1) BR112012023166A2 (es)
CA (1) CA2790183A1 (es)
IL (1) IL260192A (es)
MX (1) MX352906B (es)
SG (3) SG183375A1 (es)
WO (1) WO2011113579A2 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011113579A2 (en) * 2010-03-16 2011-09-22 European Molecular Biology Laboratory (Embl) Influenza a 2009 pandemic h1n1 polypeptide fragments comprising endonuclease activity and their use
US8859290B2 (en) * 2011-07-22 2014-10-14 Rutgers, The State University Of New Jersey Inhibitors of influenza endonuclease activity and tools for their discovery
JP6918305B2 (ja) * 2017-03-10 2021-08-11 地方独立行政法人神奈川県立産業技術総合研究所 インフルエンザウイルスの増殖を阻害するモノクローナル抗体
CN112837764B (zh) * 2021-01-21 2023-07-07 北京晶泰科技有限公司 分子杂交方法及平台

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2340475T3 (es) * 2002-05-01 2010-06-04 Vertex Pharmaceuticals Incorporated Estructura cristalizada de proteina aurora-2 y sus bolsillos de union.
CA2701362A1 (en) * 2007-10-09 2009-04-16 European Molecular Biology Laboratory (Embl) Soluble fragments of influenza virus pb2 protein capable of binding rna-cap
CN101514335B (zh) * 2008-02-22 2013-04-17 中国科学院生物物理研究所 流感病毒聚合酶亚基pa的表达纯化及pa氨基端及pa羧基端与pb1氨基端多肽复合体的晶体结构
WO2011113579A2 (en) 2010-03-16 2011-09-22 European Molecular Biology Laboratory (Embl) Influenza a 2009 pandemic h1n1 polypeptide fragments comprising endonuclease activity and their use

Also Published As

Publication number Publication date
WO2011113579A2 (en) 2011-09-22
IL260192A (en) 2018-07-31
US9181307B2 (en) 2015-11-10
EP2547696A2 (en) 2013-01-23
JP2013521786A (ja) 2013-06-13
BR112012023166A2 (pt) 2020-08-25
MX2012010652A (es) 2013-02-07
CN105273066A (zh) 2016-01-27
AU2011229469A1 (en) 2012-09-06
AU2011229469B2 (en) 2015-01-22
CA2790183A1 (en) 2011-09-22
SG183375A1 (en) 2012-09-27
SG10201703245SA (en) 2017-05-30
US20160053241A1 (en) 2016-02-25
US9783794B2 (en) 2017-10-10
CN102803288A (zh) 2012-11-28
KR20130075726A (ko) 2013-07-05
EP2547696B1 (en) 2018-05-23
SG10201601365RA (en) 2016-03-30
US20130023565A1 (en) 2013-01-24
CN102803288B (zh) 2015-09-23
JP2016189772A (ja) 2016-11-10
US20180044649A1 (en) 2018-02-15
WO2011113579A3 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
MX2021007679A (es) Anticuerpos humanos para hemaglutinina de influenza.
EA201490654A1 (ru) Новые ингибиторы вирусной репликации
EA029939B8 (ru) Человеческие связывающие молекулы, обладающие способностью нейтрализовывать вирус гриппа h3n2, и их применение
BR112015022790A8 (pt) molécula biespecífica, composição farmacêutica, método de tratamento de uma infecção por vírus latente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus persistente em um indivíduo em necessidade de tal tratamento, método de tratamento de uma infecção por vírus inativo em um indivíduo em necessidade de tal tratamento, método para exterminar uma célula que contém um genoma viral, e, método para exterminar uma célula que expressa uma proteína viral
EP3816288A3 (en) Modulation of hepatitis b virus (hbv) expression
Sakabe et al. A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection
GB0921730D0 (en) Method of treatment
PH12015502230A1 (en) Novel viral replication inhibitors
BR112017024481A2 (pt) inibidores de ebna1 e métodos de uso dos mesmos
WO2010069600A3 (en) Polypeptide fragments comprising endonuclease activity and their use
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
MX352906B (es) Fragmentos de la subunidad pa de rna polimerasa dependiente de rna del virus pandemico h1n1 2009 de influenza a y su uso.
EA201290897A1 (ru) Вакцины для пандемического гриппа
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
Su et al. Emergence and pandemic potential of avian influenza a (H7N9) virus
Meseko et al. Preventing zoonotic influenza
Masoodi et al. Comparative analysis of hemagglutinin of 2009 H1N1 influenza A pandemic indicates its evolution to 1918 H1N1 pandemic
EA201792482A1 (ru) Соединения-пептидомиметики, нейтрализующие вирус гриппа
WO2018056528A3 (ko) 인플루엔자 b 백신
Manohar In silico analysis of compounds from Stemona tuberosa as an inhibitor for N1 neuraminidase of H5N1 avian virus
MX2019011324A (es) Bloqueo de cxcr4/cxcr7 y tratamiento de enfermedad asociada con el virus del papiloma humano.
Mebratu et al. Bcl-2 Interacting Killer (BIK) Augments Influenza A Virus Replication and Severity of Flu
del Campo La nueva gripe A/H1N1 o gripe A/H1N1 (2009)
PH12019501907A1 (en) Novel viral replication inhibitors
SAXENA et al. A global comparison and analysis of neuraminidase H1N1 strain of influenza A

Legal Events

Date Code Title Description
FG Grant or registration